CN116178408A - Criborotate and crystal form, preparation method and application thereof - Google Patents
Criborotate and crystal form, preparation method and application thereof Download PDFInfo
- Publication number
- CN116178408A CN116178408A CN202310033870.8A CN202310033870A CN116178408A CN 116178408 A CN116178408 A CN 116178408A CN 202310033870 A CN202310033870 A CN 202310033870A CN 116178408 A CN116178408 A CN 116178408A
- Authority
- CN
- China
- Prior art keywords
- salt
- crystalline form
- clenbuterol
- piperazine
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 229960001117 clenbuterol Drugs 0.000 claims abstract description 22
- -1 clenbuterol piperazine salt Chemical group 0.000 claims abstract description 13
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 9
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 9
- 229960002626 clarithromycin Drugs 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000002002 slurry Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 238000004566 IR spectroscopy Methods 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 13
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000004458 analytical method Methods 0.000 description 8
- 238000001907 polarising light microscopy Methods 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- USZAGAREISWJDP-UHFFFAOYSA-N crisaborole Chemical compound C=1C=C2B(O)OCC2=CC=1OC1=CC=C(C#N)C=C1 USZAGAREISWJDP-UHFFFAOYSA-N 0.000 description 1
- 229950008199 crisaborole Drugs 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/023—Preparation; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a clenbuterol piperazine salt and a crystal form thereof, a preparation method and application thereof. The clenbuterol piperazine salt and the crystal form thereof provided by the invention have the advantages of better stability, better solubility and the like, and are beneficial to improving the bioavailability of the medicine, thereby improving the efficacy of the medicine.
Description
The application is a divisional application with the application date of 2022, 12 months and 30 days, the application number of CN202211732252.4, and the name of the patent is clenbuterol salt and crystal forms, preparation methods and application thereof.
Technical Field
The invention relates to the technical field of pharmaceutical chemistry, in particular to a clenbuterol piperazine salt and a crystal form, a preparation method and application thereof.
Background
In month 2016, the U.S. Food and Drug Administration (FDA) approved the use of the Anacor company's Crisabole ointment (trade name Eucrisa), a non-steroidal PDE-4 inhibitor, for the treatment of atopic dermatitis, having the formula:
disclosure of Invention
The invention provides a clenbuterol piperazine salt and a crystal form thereof, which have at least one of the following advantages: good solubility in water, good stability, good dissolution, high purity, low hygroscopicity and good fluidity, meets the requirements of medicine, can be stably stored, has simple preparation mode and high bioavailability, and is suitable for industrial production and the like.
In a first aspect of the present invention, there is provided a salt of cliboropiperazine having the structural formula (I),
a crystalline Form of a salt of cliboropiperazine of the first aspect of the present invention, the crystalline Form being Form I, having at least one characteristic diffraction peak selected from 10.42±0.2°, 13.77±0.2°, 14.22±0.2°, and 20.07±0.2° in an X-ray powder diffraction pattern (XRPD) expressed as diffraction angle 2θ; preferably at least three characteristic diffraction peaks.
Preferably, the crystal Form I further has at least one characteristic diffraction peak selected from the group consisting of 15.65±0.2°, 17.67±0.2°, 18.19±0.2° and 25.15±0.2° in an X-ray powder diffraction pattern expressed by a diffraction angle 2θ.
Preferably, the crystal Form I further has at least one characteristic diffraction peak selected from 16.47±0.2°, 22.25±0.2°, 26.09±0.2° and 26.55±0.2° in an X-ray powder diffraction pattern expressed by a diffraction angle 2θ.
Preferably, the X-ray powder diffraction data for Form I are shown in table 1.
Preferably, the Form I has an X-ray powder diffraction pattern substantially as shown in figure 1.
Preferably, the Form I is a Form I which is selected from 3255.96cm in Fourier IR spectroscopy -1 ±2cm -1 、3045.12cm -1 ±2cm -1 、2847.14cm -1 ±2cm -1 、2718.09cm -1 ±2cm -1 、1470.43cm -1 ±2cm -1 、1415.23cm -1 ±2cm -1 、1388.20cm -1 ±2cm -1 、1108.24cm -1 ±2cm -1 、1061.31cm -1 ±2cm -1 、1036.14cm -1 ±2cm -1 、833.31cm -1 ±2cm -1 、783.53cm -1 ±2cm -1 、710.01cm -1 ±2cm -1 Having a characteristic peak at least one of them.
Preferably, the Form I has a fourier infrared spectrum as shown in fig. 6.
Preferably, the Form I is anhydrate.
Preferably, the Form I has a TGA profile substantially as shown in figure 2.
Preferably, the Form I has a DSC profile substantially as shown in figure 3.
Preferably, the Form I has a DVS profile substantially as shown in figure 4.
In a second aspect of the present invention, there is provided a method for preparing a salt of clavulanic piperazine according to the first aspect, comprising the steps of: adding the clenbuterol and piperazine into a solvent to obtain a suspension, stirring until solid is separated out, separating, and drying to obtain the finished product; preferably, the solvent is an organic solvent.
The invention further provides a preparation method of the crystal Form I of the clenbuterol piperazine salt in the first aspect, which comprises the following steps:
adding the clenbuterol and piperazine into an organic solvent to obtain a suspension, carrying out crystal slurry, separating and drying to obtain the crystal form.
Preferably, the crystalline Form I of the salts of cliboropiperazine comprises the steps of: adding the clenbuterol and piperazine into an organic solvent to obtain a suspension, separating solids from crystal slurry which is more than or equal to 1h, and drying to obtain the crystal form.
Preferably, the crystal mush is more than or equal to 6 hours, more preferably, the crystal mush is more than or equal to 1 day; most preferably 2-5 days.
Preferably, the crystal slurry is room temperature crystal slurry.
Preferably, the solvent can be supplemented in the crystal slurry process.
Preferably, in the above preparation method, the organic solvent is one or a mixed solvent of ethers and esters; more preferably, the solvent is selected from tetrahydrofuran and ethyl acetate or a mixed solvent of both.
Preferably, in the preparation method, the mass-volume ratio (mg/mL) of the clenbuterol to the solvent is preferably more than or equal to 50:1, more preferably 60 to 120.
Preferably, in the preparation method, the molar ratio of the clenbuterol to the piperazine is 1-5:1, more preferably 1.5-3:1, and even more preferably 1.9-2.2:1;
preferably, in the above preparation method, the drying temperature is 40 to 70 ℃, still preferably 45 to 55 ℃, further preferably 48 to 52 ℃.
The clenbuterol piperazine salt and the crystal form thereof have the following beneficial effects:
1) The salt and the crystal form thereof have good stability. The crystal Form I is kept unchanged after being placed for 21 days under the conditions of long term and acceleration, so that the Form I bulk drug has good crystal Form stability and chemical stability.
2) The salt and the crystal form thereof have good water solubility, and are beneficial to improving the bioavailability of the clenbuterol medicine, thereby improving the patentability and the efficacy of the medicine; the dosage of the medicine is reduced while the curative effect of the medicine is ensured, thereby reducing the side effect of the medicine and improving the safety of the medicine.
3) The salt and the crystal form thereof hardly absorb moisture, do not need to strictly control humidity, and are more suitable for industrial production.
4) The salt and the crystal form thereof have almost no solvent residue and meet the medicinal requirements.
In a third aspect of the present invention, there is provided a pharmaceutical composition comprising a salt of clavulanic piperazine according to the first aspect or/and a crystalline form thereof and at least one pharmaceutically acceptable carrier.
In the present invention, pharmaceutically acceptable carriers include diluents or excipients or other additives, examples of which include, but are not limited to, for example, wetting agents, disintegrants, lubricants, binders, surfactants, and the like. Examples of other additives include, but are not limited to, for example, shellac, gum arabic, talc, titanium oxide, sugar (e.g., sucrose), gelatin, water, polysaccharides such as lactose or glucose, paraffin (e.g., petroleum fractions), vegetable oils (e.g., peanut oil or sesame oil), and pharmaceutically acceptable organic solvents such as alcohols (e.g., ethanol or glycerol), natural mineral powders (e.g., kaolin, clay, talc, and chalk), synthetic mineral powders (e.g., highly dispersed silicic acid and silicates), emulsifiers (e.g., lignin, sulfite solutions, methyl cellulose, starch, and polyvinylpyrrolidone), magnesium stearate, stearic acid, sodium lauryl sulfate, and the like.
The pharmaceutical composition of the present invention may be prepared in various dosage forms including, but not limited to, semi-solid pharmaceutical preparations suitable for topical skin administration, such as ointments, gels, creams, and the like, or pharmaceutical preparations suitable for oral administration, such as solid oral preparations including tablets, coatings, capsules, granules, powders, pills, powders, and the like, or liquid oral preparations including solutions, syrups, suspensions, emulsions, and the like; pharmaceutical preparations suitable for parenteral administration, for example intravenous drip preparations, intramuscular or subcutaneous preparations, suppositories for rectal administration, inhalant preparations for intranasal administration, or further transdermal patch forms for topical administration. In the preparation production, additional auxiliary materials can be further included, and preferably, the addition of the auxiliary materials does not cause the transformation of the crystal forms.
Preferably, the pharmaceutical composition of the present invention is an ointment.
In a fourth aspect of the invention, there is provided the use of a salt of clarithromycin and a crystalline form thereof according to the first aspect in the manufacture of a topical pharmaceutical formulation for the treatment of an inflammation-related disorder or condition including psoriasis and atopic dermatitis.
Preferably, the present invention provides the use of a salt of clarithromycin and a crystalline form thereof according to the first aspect in the manufacture of a medicament for the prevention or treatment of a phosphodiesterase 4 (PDE-4) related disease.
In a fifth aspect of the invention, there is provided a method for preventing or treating a disease comprising the step of administering to a subject in need thereof the salt of clavulanic piperazine as defined in the first aspect and its crystalline form or the pharmaceutical composition as defined in the third aspect, wherein the disease is a phosphodiesterase 4-related disease comprising psoriasis and an inflammatory-related disease of atopic dermatitis. Preferably, the pharmaceutical composition comprises a prophylactically and/or therapeutically effective amount of a salt of tolibupropium and crystalline forms thereof.
In a sixth aspect of the invention there is provided the use of a salt of clarithromycin according to the first aspect and a crystalline form thereof or a pharmaceutical composition according to the third aspect in combination with other pharmaceutically active ingredients.
Drawings
FIG. 1 is an XRPD pattern for Form I of a crystalline Form of creboropiperazine salt prepared according to example 1.
FIG. 2 is a TGA spectrum of crystalline Form I of the salt of toliprazine prepared according to example 1.
FIG. 3 is a DSC graph of Form I of the crystalline Form of the salt of tolibupropium prepared according to example 1.
Fig. 4 is a DVS spectrum of crystalline Form I of creboropiperazine salt prepared according to example 1.
Fig. 5 is a PLM spectrum of crystalline Form I of the salt of toliprazine prepared according to example 1.
Fig. 6 is a fourier infrared spectrum of crystalline Form I of the salt of creboropiperazine prepared according to example 1.
FIG. 7 is a single crystal PLM spectrum of Form I of the crystalline Form of the salts of creboropiperazine.
Fig. 8 is an XRPD pattern of crystalline Form I of creboropiperazine salt before and after placement under accelerated and prolonged conditions.
Detailed Description
Various exemplary embodiments of the invention will now be described in detail, which should not be considered as limiting the invention, but rather as more detailed descriptions of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In addition, for numerical ranges in the present invention, it is understood that the upper and lower limits of the ranges and each intermediate value therebetween are specifically disclosed. Every smaller range between any stated value or stated range, and any other stated value or intermediate value within the stated range, is also encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control. Unless otherwise indicated, "%" is percent by weight.
In the process according to the invention, the salts according to the invention and the crystalline forms thereof are generally prepared starting from Crisabelole, which is obtainable either from commercial products or from the process described in patent application WO2006/089067 by the company Anacor Pharmaceutical, and piperazine as starting material is obtainable from commercial products.
The term "subject" as used herein includes mammals. The mammal may be, for example, any mammal, e.g., human, primate, bird, mouse, rat, poultry, dog, cat, cow, horse, goat, camel, sheep, or pig. Preferably the mammal is a human.
The term "room temperature" as used herein generally refers to 10-30℃and preferably 20.+ -. 5 ℃.
In the present invention, the term "crystalline form" refers to a certain lattice configuration of a crystalline substance. It is known in the art that crystalline forms are related to stability, dissolution and mechanical properties in the manufacture of a medicament. Different crystal forms of the same substance typically have different lattices (e.g., unit cells) with different physical properties that are characteristic thereof. The different crystal forms may be characterized by methods known in the art. For example, it can be identified by solid state characterization methods, such as by X-ray powder diffraction (XRPD). Other characterization methods include Differential Scanning Calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor adsorption (DVS), solid state NMR, and the like. The crystalline form may be characterized using any of the methods described above, or by using two or more methods in combination.
Other experimental methods are known in the art, except for the specific description of the present invention, and reference is made to, for example, the pharmacopoeia of the people's republic of China. Wherein, the parameters for detection are set as follows:
specific conditions for XRPD (X-ray powder diffraction) measurement are: bruker D8, cu-K alpha radiation, detection range of 3-40 degrees 2 theta, step length of 0.02 degrees 2 theta and scanning speed of 0.2s.step-1.
Thermogravimetric analysis (TGA) data were taken from TA Instruments Q500TGA. The parameters are as follows:
scanning rate: at 10 ℃/min; protective gas: n (N) 2 。
Differential thermal analysis (DSC) data were taken from TA Instruments Q200 DSC. The parameters are as follows:
scanning rate: at 10 ℃/min; protective gas: n (N) 2 。
Dynamic moisture sorption analysis (DVS) data and isothermal sorption analysis data were taken from TA Instruments Q5000SA. The parameters are as follows:
temperature: 25 ℃; relative humidity range: 0% RH-80% RH.
Polarized Light Microscopy (PLM) spectra were taken from XP-500E polarized light microscopy. A small amount of powder sample is taken and placed on a glass slide, a small amount of mineral oil dispersion sample is dripped, a cover slip is covered, and the glass slide is placed on a stage for observation and photographing.
The test conditions for fourier infrared spectroscopy were: bruker tensor 27, ATR method, resolution 4cm -1 。
In the present invention, the terms "property" or "crystalline form property" or "pharmaceutical property" include physical and chemical properties thereof, and evaluation indexes include, but are not limited to, for example, melting point, water solubility, dissolution rate, mechanical properties, stability, pharmacokinetics or pharmacodynamics, hygroscopicity, flowability, compressibility, competitiveness, and the like.
The various reagents used in the examples were commercially available unless otherwise specified. Unless otherwise indicated, the examples were all run at room temperature.
Example 1
About 60.67mg of the clenbuterol and 10.76mg of piperazine are taken, 0.7mL of tetrahydrofuran is added, the mixture is stirred at room temperature to obtain white suspension, after stirring at room temperature for 2 days, a large amount of solids are separated out, 2mL of tetrahydrofuran solvent is added into the suspension, stirring at room temperature is continued for 1 day, centrifugal filtration is carried out, and the obtained solid is dried at 50 ℃ in vacuum for 1 hour to obtain the crystal Form I of the clenbuterol piperazine salt.
The sample of example 1 was taken for characterization, as follows.
1. XRPD pattern analysis
FIG. 1 is an XRPD pattern for Form I, and Table 1 shows the X-ray powder diffraction data for Form I.
Table 1: x-ray powder diffraction data for Form I
2. TGA profile analysis
The TGA results are shown in figure 2. The weight loss step is arranged before 94 ℃, the weight loss rate is 0.5 percent, and the weight loss step is arranged between 94 ℃ and 150 ℃, and the weight loss rate is 10.2 percent.
3. DSC analysis of the spectrum
The result of the differential calorimetric scan analysis is shown in FIG. 3. Form I has a piperazine dissociation temperature of 102 ℃, melts at 213 ℃ and accompanies decomposition.
4. DVS profile analysis
The DVS analysis results are shown in fig. 4. Form I absorbs about 0.3% moisture at 80% rh, and exhibits little hygroscopicity.
5. PLM analysis
The Polarized Light Microscope (PLM) results are shown in fig. 5, which shows fine particles.
6. FT-IR analysis
The fourier infrared spectrum results are shown in fig. 6.
7. Single crystal PLM pattern
The single crystal cultivation method is as follows: 10mg of the sample prepared in example 1 was placed in a glass vial, dissolved with 3.4mL of ethyl acetate by sonication, and filtered using a syringe with a 0.45 μm filter head. And placing the obtained clear solution at room temperature for small pore volatilization to obtain a blocky crystal, and carrying out structural characterization on the obtained monocrystal. The single crystal pattern is shown in fig. 7, and the clenbuterol: piperazine = 2:1 and is coordinately and covalently bonded (n→b), which has the single crystal structure data of table 2.
TABLE 2 Single Crystal Structure information Table of Crystal Form I
Example 2
60.38mg of clenbuterol and 10.59mg of piperazine are taken, 0.9mL of ethyl acetate is added, the mixture is stirred at room temperature to obtain a white suspension, after stirring at room temperature for 2 days, a large amount of solids are separated out, 2mL of ethyl acetate solvent is added into the suspension, stirring at room temperature is continued for 1 day, centrifugal filtration is carried out, and the obtained solid is dried at 50 ℃ in vacuum for 1 hour to obtain clenbuterol piperazine salt Form I.
Example 3
Taking 5mg of Form I sample prepared in example 1, placing under acceleration (40 ℃,75% RH, open light shielding) and long term (25 ℃,60% RH, open light shielding) conditions respectively, and the results show that: form I remained unchanged for 21 days under accelerated and long term conditions, indicating that Form I was stable and the XRPD pattern of the sample stability test is shown in fig. 8.
While the invention has been described with reference to exemplary embodiments, it is to be understood that the invention is not limited to the disclosed exemplary embodiments. Various modifications or changes may be made to the exemplary embodiments of the present disclosure without departing from the scope or spirit of the invention. The scope of the claims is to be accorded the broadest interpretation so as to encompass all modifications and equivalent structures and functions.
Claims (10)
2. a crystalline form of a salt of clarithromycin according to claim 1, having at least one characteristic diffraction peak selected from the group consisting of 10.42±0.2°, 13.77±0.2°, 14.22±0.2° and 20.07±0.2° in an X-ray powder diffraction pattern expressed as diffraction angle 2Θ; preferably three characteristic diffraction peaks.
3. The crystalline form of claim 2, further having at least one characteristic diffraction peak selected from the group consisting of 15.65±0.2°, 17.67±0.2°, 18.19±0.2° and 25.15±0.2° in an X-ray powder diffraction pattern expressed as diffraction angle 2Θ; alternatively, the optical element further has at least one characteristic diffraction peak selected from 16.47 + -0.2 DEG, 22.25 + -0.2 DEG, 26.09 + -0.2 DEG, and 26.55 + -0.2 deg.
4. A crystalline form of clarithromycin salt as claimed in any one of claims 2-3 which is characterized by a composition selected from the group consisting of 3255.96cm in fourier infrared spectroscopy -1 ±2cm -1 、3045.12cm -1 ±2cm -1 、2847.14cm -1 ±2cm -1 、2718.09cm -1 ±2cm -1 、1470.43cm -1 ±2cm -1 、1415.23cm -1 ±2cm -1 、1388.20cm -1 ±2cm -1 、1108.24cm -1 ±2cm -1 、1061.31cm -1 ±2cm -1 、1036.14cm -1 ±2cm -1 、833.31cm -1 ±2cm -1 、783.53cm -1 ±2cm -1 、710.01cm -1 ±2cm -1 Having a characteristic peak at least one of them.
5. A process for the preparation of a salt of cliboropiperazine according to claim 1, characterized in that it comprises the steps of: adding the clenbuterol and piperazine into a solvent to obtain a suspension, stirring until solid is separated out, separating, and drying to obtain the finished product; preferably, the solvent is an organic solvent.
6. A process for the preparation of a crystalline form of a salt of clarithromycin according to any one of claims 2-4 comprising the steps of:
adding the clenbuterol and piperazine into an organic solvent to obtain a suspension, carrying out crystal slurry, separating and drying to obtain the crystal form.
7. The method according to claim 5 or 6, wherein the organic solvent is one or a mixed solvent of ethers and esters; preferably, the organic solvent is selected from tetrahydrofuran and ethyl acetate or a mixed solvent of the tetrahydrofuran and the ethyl acetate, preferably, the molar ratio of the clenbuterol to the piperazine is 1-5:1, preferably 1.5-3:1, and further preferably 1.9-2.2:1; preferably, the mass-to-volume ratio (mg/mL) of the clenbuterol to the solvent or the organic solvent is more than or equal to 50:1, more preferably 60-120; preferably, the drying temperature is 40-70 ℃, still preferably 45-55 ℃, still more preferably 48-52 ℃.
8. The method of claim 7, wherein the slurry is not less than 1h, more preferably not less than 6h, most preferably not less than 1-5 days.
9. A pharmaceutical composition comprising a salt of clarithromycin according to claim 1 or/and a crystalline form according to any one of claims 2-5 and at least one pharmaceutically acceptable carrier.
10. Use of the salts of clarithromycin according to claim 1 or of the crystalline form of any one of claims 2 to 5 in the manufacture of a topical pharmaceutical formulation for the treatment of an inflammation-related disease or disorder, wherein the inflammation-related disease or disorder includes psoriasis and atopic dermatitis; preferably, the use of a salt of clarithromycin according to claim 1 or/and a crystalline form according to any one of claims 2 to 5 or a pharmaceutical composition according to claim 9 in combination with other pharmaceutically active ingredients.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111677660 | 2021-12-31 | ||
CN202111677660X | 2021-12-31 | ||
CN202211732252.4 | 2022-12-30 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211732252.4 Division | 2021-12-31 | 2022-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116178408A true CN116178408A (en) | 2023-05-30 |
Family
ID=86469457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310033870.8A Pending CN116178408A (en) | 2021-12-31 | 2022-12-30 | Criborotate and crystal form, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116178408A (en) |
-
2022
- 2022-12-30 CN CN202310033870.8A patent/CN116178408A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100588254B1 (en) | Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamid | |
JP4138886B2 (en) | Novel modification of 2-amino-4- (4-fluorobenzylamino) -1-ethoxycarbonyl-aminobenzene and process for its production | |
EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
EP0526171A2 (en) | Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them | |
EP3279188B1 (en) | Axially chiral isomers, and preparation methods therefor and pharmaceutical uses thereof | |
CN107848979A (en) | Pleasure is cut down for novel crystal forms of Buddhist nun's mesylate and preparation method thereof | |
CN110494423A (en) | The happy novel crystal forms and preparation method thereof cut down for Buddhist nun's mesylate | |
CN102325778A (en) | Nalmefene hydrochloride dihydrate | |
KR102657147B1 (en) | Crystalline form of bilastin and method for producing the same | |
US20230050777A1 (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
CN116178408A (en) | Criborotate and crystal form, preparation method and application thereof | |
CN106279169B (en) | Novel crystal form of istradefylline and preparation method thereof | |
KR101408370B1 (en) | Material containing aripiprazole and organic acid cocrystals and method for making thereof | |
WO2012160568A1 (en) | Process for preparing docetaxel trihydrate polymorph | |
WO2018214877A1 (en) | Crystal form of dezocine and preparation method therefor | |
CN113004198B (en) | Hydroxytyrosol nicotinamide eutectic crystal, preparation method and composition thereof | |
CN108570045B (en) | Crystal form of anisodamine hydrobromide, preparation method and pharmaceutical composition thereof | |
EP3083552B1 (en) | Stable solid forms of enclomiphene and enclomiphene citrate | |
KR20010080444A (en) | Crystalline Forms of 3-(2,4-Dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide | |
US20220177475A1 (en) | Fgfr inhibitor compound in solid form and preparation method therefor | |
CN113801189A (en) | Crystal form of factor D retarder and preparation method thereof | |
JP2022540275A (en) | Crystal form, preparation method and use of tetramethylpyrazine nitrone | |
CN113620982A (en) | Crystal form of Crisabiole solvate and preparation method and application thereof | |
CN110582279B (en) | Co-crystals of 2- (6-methyl-pyridin-2-yl) -3-yl- [ 6-amido-quinolin-4-yl ] -5, 6-dihydro-4H-pyrrolo [1,2-b ] pyrazole, methods for preparing the same and pharmaceutical compositions | |
JP2022508945A (en) | Crystal morphology of potassium channel modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |